ClinicalTrials.gg
RecruitingNCT07021820MOSAICUpdated Jun 15, 2025

Multispectral Optoacoustic Tomography for Advanced Imaging of Centronuclear Myopathy

An observational study in Centronuclear Myopathy, sponsored by University of Erlangen-Nürnberg Medical School. Recruiting at 1 site in Germany. Open to participants aged 2 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-15.

Sponsored by University of Erlangen-Nürnberg Medical School · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year ago, but the record still lists the study as recruiting.
  • Started May 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
40
Ages
2 Years and older
Sex
All
01

Study summary

Twenty patients with centronuclear myopathy and twenty age- and sex-matched, muscle-healthy controls will undergo diagnostic examination. Study participants will undergo physical examination, clinical and functional testing, and multispectral optoacoustic tomography (MSOT) scanning at predefined muscle sites (paraspinal muscles, trapezius muscle, deltoid muscle, forearm flexors, quadriceps muscle, adductor muscles, ischiocrural muscles, triceps surae muscle, and tibialis anterior).

Read the detailed description

Centronuclear myopathy (CNM) belongs to the group of congenital myopathies. These are named after their histopathological feature: the nucleus is localized in the center of the muscle cell instead of its physiological position at the periphery. CNM is so rare that there are only epidemiological data available for the group of congenital myopathies as a whole. The incidence is estimated at 0.06 per 1,000 live births.

CNM is genetically and clinically heterogeneous. Identified gene mutations affect proteins involved in membrane remodeling, transport, and excitation-contraction coupling.

Patients with CNM usually present with muscle weakness and hypotonia in early childhood. The severity of the disease varies depending on the underlying genotype and ranges from reduced exercise tolerance and ptosis to floppy infant syndrome and respiratory failure. One example of a very severe course is the X-linked form caused by a Myotubularin 1 (MTM1) nonsense mutation (XL-MTM). Affected patients become symptomatic in the neonatal period and usually die in childhood or adolescence. In contrast, patients with the Dynamin 2 (DNM2) mutation have a later onset and milder disease progression. In the few reported patients with Bridging Integrator 1 (BIN1) mutations, onset occurs in infancy or adulthood with a moderate disease course. Ryanodine receptor 1 (RYR1)-associated CNMs also vary in terms of age of onset and disease severity.

Diagnosis is based on molecular genetic testing and muscle biopsy. However, these techniques are not widely available, are time-consuming, and invasive. Anesthesia is usually required for young patients.

Multispectral optoacoustic tomography (MSOT) enables the detection of specific endogenous chromophores such as collagen, myoglobin, or hemoglobin using a non-invasive approach comparable to conventional ultrasound. Instead of sound waves, MSOT uses near-infrared light pulses that are absorbed by tissue, causing thermoelastic expansion of certain molecules. This expansion generates ultrasound waves, which are then detected by the same device. The multispectral illumination and signal unmixing enable precise localization and quantification of muscle-specific subcellular structures. MSOT has already demonstrated the potential to visualize muscle structure and disease extent in patients with Duchenne muscular dystrophy, spinal muscular atrophy, and late-onset Pompe disease (LOPD), and to distinguish these patients from healthy volunteers. To date, there are no optoacoustic data available for CNM.

The aim of this study is to gain molecular insights into muscle degeneration in CNM patients for the first time. To develop a comprehensive picture of the optoacoustic characteristics of CNM, patients of different ages and disease severities will be recruited. Due to the rarity and small number of CNM cases, recruitment is challenging. Therefore, the opportunity should be taken to offer study participation to as many patients as possible at the patient meeting in Bad Nauheim from May 29 to June 1, 2025. In addition to non-invasive, radiation-free imaging, clinical-functional tests will be conducted as part of the study. These include muscle strength testing (MRC score) and the timed "get up and go" test. Various accessible muscle groups will be scanned using MSOT, including the paraspinal muscles and trapezius muscle, as well as the following limb muscles on both sides: deltoid, biceps brachii, forearm flexors, quadriceps femoris, adductors, hamstrings (ischiocrural muscles), triceps surae, and tibialis anterior.

02

Conditions studied

  • Centronuclear Myopathy

Keywords

  • MSOT
  • centronuclear myopathy
  • MOSAIC
03

In context

Myopathies, Structural, Congenital

24 studies on the registry are indexed under Myopathies, Structural, Congenital; 10 are open to participants now.

This study's planned enrollment of 40 is below the median of 49 across 12 observational studies indexed under Myopathies, Structural, Congenital.

Browse Myopathies, Structural, Congenital studies →

Lead sponsor

University of Erlangen-Nürnberg Medical School is the lead sponsor of 277 studies on the registry; 53 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

n= 20 CNM n = 20 HV

Eligibility criteria

CNM arm:

Inclusion Criteria: diagnosed CNM; minimum of 2 years of age

Exclusion Criteria:

  • Pregnancy
  • Nursing mothers
  • Tattoo in the area of the examination field
  • Subcutaneous fatty tissue > 3 cm

HV:

Inclusion criteria: minimum of 2 years of age

Exclusion criteria:

  • any signs/history of muscle diseases
  • Pregnancy
  • Nursing mothers
  • Tattoo in the area of the examination field
  • Subcutaneous fatty tissue > 3 cm
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
40 participants (estimated)
Patient registry
No

Groups and cohorts

  • CNM

    patients with diagnosed centronuclear myopathy

    Diagnostic Test: MSOT

  • HV

    Healthy control

    Diagnostic Test: MSOT

Interventions

  • Diagnostic testMSOT

    Multispectral optoacoustic tomography (MSOT) enables the detection of specific endogenous chromophores such as collagen, myoglobin or haemoglobin using a non-invasive approach comparable to conventional ultrasound. Instead of sound waves, MSOT illuminates the tissue with near-infrared light of transient energy, which is absorbed and leads to thermoelastic expansion of certain molecules. This expansion generates ultrasound waves that are detected by the same device. The multispectral illumination and unmixing then enable the precise localization and quantification of muscle-specific subcellular structures. MSOT has already shown the potential to visualize the muscle structure and clinical extent of muscle disease in patients with Duchenne muscular dystrophy, spinal muscular atrophy and the late-onset Pompe disease (LOPD) and to distinguish these patients from healthy volunteers. To date, there is no optoacoustic data on CNM.

06

What researchers measure

Primary outcomes

  1. Optoacoustic spectrum of MSOT Imaging (all in arbitrary units)

    Comparison of optoacoustic spectrum from patients with diagnosed CNM and their age- and sex matched Healthy Volunteers

    Time frame: Day 1

Secondary outcomes

  1. Comparison of MSOT-Derived Hemoglobin and Myoglobin Signals

    Quantitative comparison of MSOT-derived hemoglobin and myoglobin signals (arbitrary units).

    Time frame: Day 1

  2. Comparison of Oxygenated vs. Deoxygenated Hemoglobin Signal

    Quantitative comparison of oxygenated and deoxygenated hemoglobin signals.

    Time frame: Day 1

  3. Comparison of Oxygenated Hemoglobin and Lipid Signal

    Quantitative comparison of oxygenated hemoglobin and lipid signals.

    Time frame: Day 1

  4. Comparison of deoxygenated Hemoglobin and Lipid Signal

    Quantitative comparison of deoxygenated hemoglobin and lipid signals.

    Time frame: Day 1

  5. Comparison of oxygenated Hemoglobin and Collagen Signal

    Quantitative comparison of oxygenated hemoglobin and collagen signals.

    Time frame: Day 1

  6. Comparison of deoxygenated Hemoglobin and Collagen Signal

    Quantitative comparison of deoxygenated hemoglobin and collagen signals.

    Time frame: Day 1

  7. Comparison of Lipid and Collagen Signal

    Quantitative comparison of Lipid and collagen signals.

    Time frame: Day 1

  8. Comparison of Lipid and Myoglobin Signal

    Quantitative comparison of Lipid and Myoglobin signals.

    Time frame: Day 1

  9. Comparison of Collagen and Myoglobin Signal

    Quantitative comparison of Collagen and Myoglobin signals.

    Time frame: Day 1

  10. Correlation of Hemoglobin Signal with Disease Duration and Patient Age

    Unit of Measure: Correlation coefficient (Pearson's r or Spearman's ρ)

    Time frame: Day 1

  11. Correlation of Myoglobin Signal with Disease Duration and Patient Age

    Unit of Measure: Correlation coefficient (Pearson's r or Spearman's ρ)

    Time frame: Day 1

  12. Correlation of oxygenated and deoxygenated Hemoglobin Signal with Disease Duration and Patient Age

    Unit of Measure: Correlation coefficient (Pearson's r or Spearman's ρ)

    Time frame: Day 1

  13. Correlation of Lipid Signal with Disease Duration and Patient Age

    Unit of Measure: Correlation coefficient (Pearson's r or Spearman's ρ)

    Time frame: Day 1

  14. Correlation of Collagen Signal with Disease Duration and Patient Age

    Unit of Measure: Correlation coefficient (Pearson's r or Spearman's ρ)

    Time frame: Day 1

  15. Correlation of Hemoglobin Signal with MRC Muscle Strength

    Unit of Measure: Correlation coefficient (MRC scale: ordinal, 1-5)

    Time frame: Day 1

  16. Correlation of Myoglobin Signal with MRC Muscle Strength

    Unit of Measure: Correlation coefficient (MRC scale: ordinal, 1-5)

    Time frame: Day 1

  17. Correlation of oxygenated and dexoygenated Hemoglobin with MRC Muscle Strength

    Unit of Measure: Correlation coefficient (MRC scale: ordinal, 1-5)

    Time frame: Day 1

  18. Correlation of Lipid Signal with MRC Muscle Strength

    Unit of Measure: Correlation coefficient (MRC scale: ordinal, 1-5)

    Time frame: Day 1

  19. Correlation of Collagen Signal with MRC Muscle Strength

    Unit of Measure: Correlation coefficient (MRC scale: ordinal, 1-5)

    Time frame: Day 1

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2025 (actual). Primary completion is estimated for Oct 2025, 5 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2025
First posted
Jun 15, 2025
StartActual
May 29, 2025
Primary completionEst.
Oct 31, 2025
CompletionEst.
Dec 31, 2026
Last update
Jun 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07021820
Responsible party
Ferdinand Knieling (Study Chair, University of Erlangen-Nürnberg Medical School) — Principal investigator
First posted
Jun 15, 2025
Start date
May 29, 2025
Primary completion
Oct 31, 2025 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jun 15, 2025

Study contacts

Lina Tan
Contact
Lina.Tan@uk-erlangen.de
+49 9131 85-41277
Ferdinand Knieling, PD Dr. med. habil. Dr. rer. b
study chair · Kinder- & Jugendklinik, Erlangen

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion